Sign in
Active, not recruitingNo phase

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

Key facts

Who runs it
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Where
Baltimore and Washington D.C., United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
40 people enrolled
Started
19 Jul 2017
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • whole brain radiation therapy
Record updated
30 June 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be obtained from either the primary or any metastatic site
  • Mini Mental State Examination (MMSE) ≥24
  • Age≥ 18 years
  • Karnofsky Performance Status (KPS) ≥70
  • Patient does not have metastases to the genu
  • Patient must be scheduled to undergo treatment with whole brain radiation therapy (WBRT) to manage the brain metastases
  • Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
  • Patient must have the ability to understand and the willingness to sign a written informed consent document
  • All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
  • Patient must have a minimal life expectancy of at least 6 months
  • Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are eligible

Who cannot take part

  • Prior WBRT
  • Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits
  • MMSE<24
  • Patient has brain metastases in the genu
  • KPS<70
  • Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks
  • Patients with absolute contraindication to MRI imaging are not eligible for the study

Where in United States

  • The SKCCC at Johns HopkinsBaltimore, United States
  • Sibley Memorial HospitalWashington D.C., United States

About the trial

What the trial wants to find out

This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.

The group in the trial

  • Corpus Callosum Genu-Sparing Whole Brain Radiation TherapyTreatment being tested

    Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction

    Treatment: whole brain radiation therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study
Record updated
30 June 2026